Mutation News and Research

RSS

Study compares mRNA and adenovirus-based SARS-CoV-2 vaccines against variants of concern

In a research paper recently uploaded to the preprint server bioRxiv by Tada et al. (July 19th, 2021) the neutralizing capacity of antibodies generated by either messenger RNA (mRNA) or adenoviral vector-based vaccines against Beta, Delta, Delta plus, and Lambda variants are investigated, among others, highlighting the importance of continued SARS-CoV-2 genomic surveillance.

26 Jul 2021

Novel microfluidic device used to manipulate major whey protein

After gaining world attention by 'unboiling' egg protein, Flinders University scientists have now used an Australian-made novel thin film microfluidic device to manipulate Beta-lactoglobulin (β-lactoglobulin), the major whey protein in cow's, sheep's and other mammals.

26 Jul 2021

CoVizu: Making visual sense of variation in SARS-CoV-2 genomes

A new study proposes a solution to this problem in the form of a new method that can both evaluate and visually represent high numbers of SARS-CoV-2 genomes.

25 Jul 2021

Activation of integrins by SARS-CoV-2 may be key to infection

A new study describes the key role of membrane proteins called integrins, which are present in epithelia, in the entry and propagation of SARS-CoV-2.

25 Jul 2021

Variations in human ACE2 genetics associated with coronavirus susceptibility

In a recent study, the researchers sought to understand the genetic variability in ACE2 that may contribute to inconsistent clinical outcomes of COVID-19.

25 Jul 2021

Study brings scientists one step closer to solving the mystery of aging

The human body is essentially made up of trillions of living cells. It ages as its cells age, which happens when those cells eventually stop replicating and dividing.

23 Jul 2021

Researchers use mass spectrometry to study immunogenic SARS-CoV-2 epitopes

A new study has been published on the bioRxiv* preprint server, which has used MS to identify T cell epitopes of SARS-CoV-2 conserved protein, i.e., the membrane glycol protein (MGP) and the non-structure protein-13 (NSP13).

23 Jul 2021

Clinical trials during a pandemic – lessons from COVID-19

In this interview, Dr. Benedicte Roquebert, Dr. Stephanie Haim-Boukobza and Dr. Souad Mehlal discuss how COVID-19 has resulted in new ways to think about clinical trials during a pandemic.

From Cerba Research 23 Jul 2021

Study: Women with breast cancer diagnosed over 65 should be offered hereditary cancer genetic testing

A new study by Fergus Couch, Ph.D., of Mayo Clinic Cancer Center, along with collaborators from the CARRIERS consortium, suggests that most women with breast cancer diagnosed over 65 should be offered hereditary cancer genetic testing.

22 Jul 2021

Chemotherapy drugs can induce mutations that lead to relapse in pediatric ALL patients

Chemotherapy has helped make acute lymphoblastic leukemia (ALL) one of the most survivable childhood cancers.

22 Jul 2021

Artificial intelligence tool enriches a gold-mine in cancer genomics

The fragments of cancer DNA analysed by the authors of this new study originate from the human genome, the sequence of which results from millions of years of evolution, and has been shaped by "copy-paste-edit" processes and co-evolution with parasitic elements.

22 Jul 2021

Finding most promising targets for pan-coronavirus drugs

Safe and effective vaccines offer hope for an end to the COVID-19 pandemic. However, the possible emergence of vaccine-resistant SARS-CoV-2 variants, as well as novel coronaviruses, make finding treatments that work against all coronaviruses as important as ever.

22 Jul 2021

Emerging SARS-CoV-2 mutations L452R & Y453F evade cellular immunity

The study, published in the journal Cell Host & Microbe, also showed emerging mutations L452R and Y453F in the SARS-CoV-2 spike receptor-binding motif evade (HLA) A24-restricted cellular immunity. Meanwhile, the L452R enhances spike stability, viral fusogenicity, and viral infectivity. Hence, the findings suggest that HLA-restricted cellular immunity potentially affects the evolution of viral phenotypes.

22 Jul 2021

Two-dose regimen of mRNA vaccines provides protection against Alpha and Beta variants in France

Over the past six months, the World Health Organization has categorized four SARS-CoV-2 variants as being "of concern" because they are more transmissible or may escape the immune response.

22 Jul 2021

SARS-CoV-2 genomic surveillance identifies intricacies of stabilizing vs. destabilizing mutations

Some of these variants, known as variants of concern (VoC), have a much higher rate of transmission and increased mortality than the original SARS-CoV-2 strain. Therefore, it is imperative to assess the efficacy of the available vaccines against the circulating SARS-CoV-2 strains. In addition, tracking the continuously evolving genetic variants is also vital to prevent future outbreaks.

22 Jul 2021

Clinical trial to test personalized treatment for severe asthma caused by a specific mutation

Under a $10 million grant, a randomized, placebo-controlled clinical trial led by Boston Children's Hospital will test a personalized treatment for a form of severe asthma to which Black and Latinx children and adults are especially vulnerable.

21 Jul 2021

Combination antibody therapies retain potency against SARS-CoV-2 variants, FDA / HHS research

Researchers in the United States have conducted a study showing that while variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can compromise the effectiveness of single therapeutic antibodies at preventing severe coronavirus disease 2019 (COVID-19), many combination antibody products remain potent against the variants.

21 Jul 2021

Study examines the host and viral factors that drive SARS-CoV-2 evolution

In a new paper recently uploaded to the preprint server bioRxiv*, two clinical isolates of SARS-CoV-2 are monitored by whole genome sequencing as they are passaged through several generations of Vero cells or human-derived primary nasal epithelial cells (PNEC), allowing direct observation of the occurrence of virus enhancing mutations and the way in which host cell factors shape virus evolution.

21 Jul 2021

Structural changes in receptor-binding interface may induce immune fitness of SARS-CoV-2 delta variant

Florida International University researchers have investigated the mutation-induced structural changes in the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could contribute to its immune evasion abilities.

20 Jul 2021

MET amplification identified as a potentially actionable driver for non-small cell lung cancer

A study led by D. Ross Camidge, MD, PhD, director of thoracic oncology at the University of Colorado School of Medicine and CU Cancer Center member, has helped to define MET amplification as a rare but potentially actionable driver for non-small cell lung cancer (NSCLC).

20 Jul 2021

Mutation News and Research

Study compares mRNA and adenovirus-based SARS-CoV-2 vaccines against variants of concern

Novel microfluidic device used to manipulate major whey protein

CoVizu: Making visual sense of variation in SARS-CoV-2 genomes

Activation of integrins by SARS-CoV-2 may be key to infection

Variations in human ACE2 genetics associated with coronavirus susceptibility

Study brings scientists one step closer to solving the mystery of aging

Researchers use mass spectrometry to study immunogenic SARS-CoV-2 epitopes

Clinical trials during a pandemic – lessons from COVID-19

Study: Women with breast cancer diagnosed over 65 should be offered hereditary cancer genetic testing

Chemotherapy drugs can induce mutations that lead to relapse in pediatric ALL patients

Artificial intelligence tool enriches a gold-mine in cancer genomics

Finding most promising targets for pan-coronavirus drugs

Emerging SARS-CoV-2 mutations L452R & Y453F evade cellular immunity

Two-dose regimen of mRNA vaccines provides protection against Alpha and Beta variants in France

SARS-CoV-2 genomic surveillance identifies intricacies of stabilizing vs. destabilizing mutations

Clinical trial to test personalized treatment for severe asthma caused by a specific mutation

Combination antibody therapies retain potency against SARS-CoV-2 variants, FDA / HHS research

Study examines the host and viral factors that drive SARS-CoV-2 evolution

Structural changes in receptor-binding interface may induce immune fitness of SARS-CoV-2 delta variant

MET amplification identified as a potentially actionable driver for non-small cell lung cancer

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Latest News